These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11290871)

  • 1. Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice.
    Desjardins JP; Abbott EA; Emerson DL; Tomkinson BE; Leray JD; Brown EN; Hamilton M; Dihel L; Ptaszynski M; Bendele RA; Richardson FC
    Anticancer Drugs; 2001 Mar; 12(3):235-45. PubMed ID: 11290871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan.
    Emerson DL; Bendele R; Brown E; Chiang S; Desjardins JP; Dihel LC; Gill SC; Hamilton M; LeRay JD; Moon-McDermott L; Moynihan K; Richardson FC; Tomkinson B; Luzzio MJ; Baccanari D
    Clin Cancer Res; 2000 Jul; 6(7):2903-12. PubMed ID: 10914740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography.
    Loos WJ; Kehrer D; Brouwer E; Verweij J; de Bruijn P; Hamilton M; Gill S; Nooter K; Stoter G; Sparreboom A
    J Chromatogr B Biomed Sci Appl; 2000 Jan; 738(1):155-63. PubMed ID: 10778937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.
    Giles FJ; Tallman MS; Garcia-Manero G; Cortes JE; Thomas DA; Wierda WG; Verstovsek S; Hamilton M; Barrett E; Albitar M; Kantarjian HM
    Cancer; 2004 Apr; 100(7):1449-58. PubMed ID: 15042679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers.
    Gelmon K; Hirte H; Fisher B; Walsh W; Ptaszynski M; Hamilton M; Onetto N; Eisenhauer E
    Invest New Drugs; 2004 Aug; 22(3):263-75. PubMed ID: 15122073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity.
    Kehrer DF; Bos AM; Verweij J; Groen HJ; Loos WJ; Sparreboom A; de Jonge MJ; Hamilton M; Cameron T; de Vries EG
    J Clin Oncol; 2002 Mar; 20(5):1222-31. PubMed ID: 11870164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts.
    Zamboni WC; Strychor S; Joseph E; Walsh DR; Zamboni BA; Parise RA; Tonda ME; Yu NY; Engbers C; Eiseman JL
    Clin Cancer Res; 2007 Dec; 13(23):7217-23. PubMed ID: 18056203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer.
    Seiden MV; Muggia F; Astrow A; Matulonis U; Campos S; Roche M; Sivret J; Rusk J; Barrett E
    Gynecol Oncol; 2004 Apr; 93(1):229-32. PubMed ID: 15047241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified lactone/carboxylate salt equilibria in vivo by liposomal delivery of 9-nitro-camptothecin.
    Chow DS; Gong L; Wolfe MD; Giovanella BC
    Ann N Y Acad Sci; 2000; 922():164-74. PubMed ID: 11193891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combination of liposomal sunitinib plus liposomal irinotecan and liposome co-loaded with two drugs enhanced antitumor activity in PC12-bearing mouse.
    Maitani Y; Saito H; Seishi Y; Iwase Y; Yamauchi T; Higashiyama K; Sugino T
    J Drug Target; 2012 Dec; 20(10):873-82. PubMed ID: 23050928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic analysis and antitumor efficacy of MKT-077, a novel antitumor agent.
    Tatsuta N; Suzuki N; Mochizuki T; Koya K; Kawakami M; Shishido T; Motoji N; Kuroiwa H; Shigematsu A; Chen LB
    Cancer Chemother Pharmacol; 1999; 43(4):295-301. PubMed ID: 10071980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.
    Schellens JH; Heinrich B; Lehnert M; Gore ME; Kaye SB; Dombernowsky P; Paridaens R; van Oosterom AT; Verweij J; Loos WJ; Calvert H; Pavlidis N; Cortes-Funes H; Wanders J; Roelvink M; Sessa C; Selinger K; Wissel PS; Gamucci T; Hanauske AR
    Invest New Drugs; 2002 Feb; 20(1):83-93. PubMed ID: 12003197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice.
    Schluep T; Cheng J; Khin KT; Davis ME
    Cancer Chemother Pharmacol; 2006 May; 57(5):654-62. PubMed ID: 16133526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan.
    Loos WJ; Verweij J; Kehrer DF; de Bruijn P; de Groot FM; Hamilton M; Nooter K; Stoter G; Sparreboom A
    Clin Cancer Res; 2002 Mar; 8(3):856-62. PubMed ID: 11895919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.
    Dark GG; Calvert AH; Grimshaw R; Poole C; Swenerton K; Kaye S; Coleman R; Jayson G; Le T; Ellard S; Trudeau M; Vasey P; Hamilton M; Cameron T; Barrett E; Walsh W; McIntosh L; Eisenhauer EA
    J Clin Oncol; 2005 Mar; 23(9):1859-66. PubMed ID: 15699482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors.
    Ramsay EC; Anantha M; Zastre J; Meijs M; Zonderhuis J; Strutt D; Webb MS; Waterhouse D; Bally MB
    Clin Cancer Res; 2008 Feb; 14(4):1208-17. PubMed ID: 18281556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts.
    Colbern GT; Dykes DJ; Engbers C; Musterer R; Hiller A; Pegg E; Saville R; Weng S; Luzzio M; Uster P; Amantea M; Working PK
    Clin Cancer Res; 1998 Dec; 4(12):3077-82. PubMed ID: 9865923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodistribution and pharmacokinetics of colon-specific HPMA copolymer--9-aminocamptothecin conjugate in mice.
    Gao SQ; Lu ZR; Kopecková P; Kopecek J
    J Control Release; 2007 Feb; 117(2):179-85. PubMed ID: 17150276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor.
    Li C; Newman RA; Wu QP; Ke S; Chen W; Hutto T; Kan Z; Brannan MD; Charnsangavej C; Wallace S
    Cancer Chemother Pharmacol; 2000; 46(5):416-22. PubMed ID: 11127947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
    Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH
    Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.